Cargando…
CD109 and squamous cell carcinoma
Squamous cell carcinoma (SCC) is well-known for its high rate of metastasis with poor prognosis. CD109 is a glycosylphosphatidylinositol-anchored cell-surface glycoprotein. Recently, CD109 emerges as a potential biomarker and a therapeutic target for SCCs. Accumulating studies have reported that CD1...
Autores principales: | Qi, Ruixia, Dong, Fengyun, Liu, Qiang, Murakumo, Yoshiki, Liu, Ju |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889571/ https://www.ncbi.nlm.nih.gov/pubmed/29625613 http://dx.doi.org/10.1186/s12967-018-1461-3 |
Ejemplares similares
-
CD109 expression is upregulated in penile squamous cell carcinoma
por: Dong, Fengyun, et al.
Publicado: (2017) -
CD109 is a novel marker for squamous cell/adenosquamous carcinomas of the gallbladder
por: Dong, Fengyun, et al.
Publicado: (2015) -
Detection of a Soluble Form of CD109 in Serum of CD109 Transgenic and Tumor Xenografted Mice
por: Sakakura, Hiroki, et al.
Publicado: (2014) -
Suppression of skin tumorigenesis in CD109-deficient mice
por: Sunagawa, Masaki, et al.
Publicado: (2016) -
CD109 regulates in vivo tumor invasion in lung adenocarcinoma through TGF‐β signaling
por: Taki, Tetsuro, et al.
Publicado: (2020)